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Background: In neuroblastoma (NB), the ALK receptor tyrosine kinase can be 
constitutively activated either through genomic amplification or activating point 
mutations. We studied ALK genetic alterations in high-risk NB patients to determine 
their frequency and prognostic impact. 
 
Methods: Diagnostic NB samples from 1039 patients enrolled in the SIOPEN-HR-
NBL1 trial were studied to determine the ALK amplification status (copy number 
analysis; n=337), the ALK mutational profile (Sanger and/or NGS including deep 
sequencing covering hotspots in exons 23-25, n=203) or both (n=499). 
 
Results: High level genomic ALK amplifications were detected in 4.4% of cases 
(37/836); all but 2 showed MYCN amplification. As for MYCN amplification, ALK 
amplification was more frequently observed in children aged<18 months at diagnosis 
(p=0.01). No correlation with the primary tumor site was observed. 
 
ALK mutations were detected at a clonal level (>10% mutated allele fraction, MAF) in 
9.8% of cases (69/702) (F1174 n= 25, R1275 n=32, both F1174 and R1275 n=1, 
F1245 n=6, others n=5). Additionally, 3.7% of patients (22/586 by NGS) harbored 
ALK mutations at a subclonal level (MAF 0.5-10%) (F1174 n=11, R1275 n=6, both 
F1174 and R1275 or F1174 and F1245 n=3, other n=2). Although not statistically 
significant, ALK mutations were observed slightly more frequently in non-adrenal 
compared to adrenal primary tumors (p=0.08).  
 
Whereas no statistically significant difference in survival was observed between 
patients with and without ALK mutations, patients with ALK amplification had a 
significantly poorer event free (EFS) and overall survival compared to those without 
ALK amplification (logrank, p<0.0001).  
 
A multivariate analysis was performed to determine which parameters independently 
predicted EFS in this high risk population. Among 450 patients with complete 
datasets, a Cox proportional hazards procedure retained stage 4 disease (as 
opposed to non-stage 4) and ALK amplification as factors with a higher hazard of 
relapse/progression (hazard 2.3 and 2.2, respectively), whereas ALK mutation, 
MYCN amplification and age>18 months were not retained. 
 
Conclusion: Taking into account amplifications, clonal and subclonal mutations, 
genetic alterations of ALK were observed in tumor samples of 17% of high-risk NB 
patients, of importance when considering ALK targeted therapies. Among the 
different genetic alterations, only ALK amplification predicted poorer survival. 
 
 
